---
$id: https://graph.org.ai/products/commodity/51343005
$type: Product
source: UNSPSC
code: "51343005"
title: "Stavudine and lamivudine and nevirapine"
class: "51343000"
classTitle: "Antiviral pyridines"
family: "51340000"
familyTitle: "Antiviral drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Stavudine and lamivudine and nevirapine

**UNSPSC Code**: 51343005
**Class**: [Antiviral pyridines](Antiviral pyridines.mdx)
**Family**: [Antiviral drugs](../Antiviral drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a combination drug for treatment of HIV. The first component of this combination drug is a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BO9LE4QFZF. European Medicines Agency schedules Stavudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10642MIG. Stavudine generally arises in the molecular formula C10H12N2O4. The term STAVUDINE is an International Non-Proprietary Name or INN. STAVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO. The second component of this drug is a reverse transcriptase inhibitor with the molecular formula C8H11N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2T8Q726O95, chemically known as 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone but generally known as lamivudine, which bears US NIH Compound Identifier 60825. European Medicines Agency schedules Lamivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08392MIG. The term LAMIVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules lamivudine in its Anatomical Therapeutic Chemical (ATC) Classification. LAMIVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. The third component of this combination drug is a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99DK7FVK1H. European Medicines Agency schedules Nevirapine, anhydrous in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25191. Nevirapine generally arises in the molecular formula C15H14N4O. The term 'nevirapine' is a European Pharmacopoeia designation. NEVIRAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

